Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin F Gainor

Showing results (1-10 of 219) with videos related to

Pageof 22
Sort By:
Cancer Cytopathology|June 17, 2017
Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?Justin F Gainor
Lancet (London, England)|September 23, 2021
Adjuvant PD-L1 blockade in non-small-cell lung cancerJustin F Gainor
Journal of Thoracic Disease|March 31, 2018
Square peg, round hole? Programmed death-1 inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancerJustin F Gainor
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2016
Moving Programmed Death-1 Inhibitors to the Front Lines in Non-Small-Cell Lung CancerJustin F Gainor
The Oncologist|September 11, 2012
Is there an app for that?Justin F Gainor
Translational Lung Cancer Research|July 15, 2016
Alectinib-a new chapter in the management of ALK-positive lung cancerJustin F Gainor
Translational Lung Cancer Research|February 11, 2021
Endocrine immune-related adverse events: a double-edged sword?Michelle Rengarajan, Justin F Gainor
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2023
Facts and Hopes: Immunocytokines for Cancer ImmunotherapyAliyah Pabani, Justin F Gainor
Cancer Journal (Sudbury, Mass.)|December 10, 2020
Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer: Implications for Oncogene-Driven Lung CancerAlexander Gavralidis, Justin F Gainor
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2022
Searching for Synergy: Chemotherapy and Checkpoint InhibitorsDiane Tseng, Justin F Gainor
Pageof 22

Showing results (1-10 of 219) with videos related to

Sort By:
Pageof 22
Cancer Cytopathology|June 17, 2017
Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?Justin F Gainor
Lancet (London, England)|September 23, 2021
Adjuvant PD-L1 blockade in non-small-cell lung cancerJustin F Gainor
Journal of Thoracic Disease|March 31, 2018
Square peg, round hole? Programmed death-1 inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancerJustin F Gainor
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2016
Moving Programmed Death-1 Inhibitors to the Front Lines in Non-Small-Cell Lung CancerJustin F Gainor
The Oncologist|September 11, 2012
Is there an app for that?Justin F Gainor
Translational Lung Cancer Research|July 15, 2016
Alectinib-a new chapter in the management of ALK-positive lung cancerJustin F Gainor
Translational Lung Cancer Research|February 11, 2021
Endocrine immune-related adverse events: a double-edged sword?Michelle Rengarajan, Justin F Gainor
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2023
Facts and Hopes: Immunocytokines for Cancer ImmunotherapyAliyah Pabani, Justin F Gainor
Cancer Journal (Sudbury, Mass.)|December 10, 2020
Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer: Implications for Oncogene-Driven Lung CancerAlexander Gavralidis, Justin F Gainor
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2022
Searching for Synergy: Chemotherapy and Checkpoint InhibitorsDiane Tseng, Justin F Gainor
Pageof 22